EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Country mission Latvia: HIV, STI and hepatitis B and C
This report describes a country mission undertaken by ECDC in 2011 to Latvia, to address issues relating to HIV, STI and hepatitis B and C identified by the Latvian government.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA: Executive summary
Hepatitis B and C surveillance in Europe 2012
This is the second report on the enhanced surveillance of hepatitis B and C viral infections. It describes basic epidemiological features and trends of both diseases across countries in the EU/EEA for 2012.
HIV and hepatitis B and C in Latvia
At the request of the Ministry of Health in Riga, a team of experts from ECDC and the European Monitoring Centre for Drugs and Drug Addiction paid a technical visit to Latvia on 2–4 September 2014.
Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies
This literature review answers a series of questions on the prevalence of chronic HBV and HCV infection in the general EU population, the number of individuals with chronic HBV or HCV infection, and current national practices for screening for chronic HBV and HCV infection, all with the overarching goal of promoting national and European policies on the secondary prevention of these two diseases.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.